Cargando…

New developments in treatment of ovarian carcinoma: focus on trabectedin

Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft tissue sarcoma, and ovarian and breast cancer, and combination with various oth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cassier, Philippe A, Duret, Aude, Trédan, Olivier, Carrabin, Nicolas, Méeus, Pierre, Treilleux, Isabelle, Guastalla, Jean-Paul, Ray-Coquard, Isabelle
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004573/ https://www.ncbi.nlm.nih.gov/pubmed/21188115 http://dx.doi.org/10.2147/CMR.S9459

Ejemplares similares

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
por: Hodroj, Khalil, et al.
Publicado: (2021)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
por: Levard, Alice, et al.
Publicado: (2013)

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
por: Cassier, Philippe A, et al.
Publicado: (2011)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012)

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value
por: Jiang, Xiaojun, et al.
Publicado: (2015)

Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin
por: Amant, Frédéric, et al.
Publicado: (2015)

Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France
por: Huguet, Marius, et al.
Publicado: (2018)

Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)
por: Derbel, Olfa, et al.
Publicado: (2017)

Update on new treatments for rare ovarian tumours
por: Quesada, Stanislas, et al.
Publicado: (2023)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
por: Mery, Benoîte, et al.
Publicado: (2023)

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients
por: Kassem, Loay, et al.
Publicado: (2015)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
por: Fumet, Jean-David, et al.
Publicado: (2022)

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
por: de la Fouchardière, Christelle, et al.
Publicado: (2022)

Validation of prognostic scores for survival in cancer patients beyond first-line therapy
por: Trédan, Olivier, et al.
Publicado: (2011)

Frequency of Asbestos Exposure and Histological Subtype of Ovarian Carcinoma
por: Vidican, Pauline, et al.
Publicado: (2022)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
por: Gadducci, Angiolo, et al.
Publicado: (2022)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
por: Belbaraka, Rhizlane, et al.
Publicado: (2010)

Efficacy of trabectedin in metastatic solitary fibrous tumor
por: Chaigneau, Loïc, et al.
Publicado: (2011)

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial
por: Pérol, David, et al.
Publicado: (2012)

Activation of rapid oestrogen signalling in aggressive human breast cancers
por: Poulard, Coralie, et al.
Publicado: (2012)

Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer
por: Poulard, Coralie, et al.
Publicado: (2019)

ERα-36 regulates progesterone receptor activity in breast cancer
por: Konan, Henri-Philippe, et al.
Publicado: (2020)

The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin
por: Jones, Robin L., et al.
Publicado: (2019)

Role of JMJD6 in Breast Tumourigenesis
por: Poulard, Coralie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_efntm0p1p7npc98mojhe62o2g0